Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

EXCLUSIVE: L.A. publisher Gungnir is launching an animation studio that will feed an in-house YouTube channel that planned as “the Cartoon Network of the digital era.” Gungnir Animation Studio will ...

The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain monoclonal antibodies (mAbs), the latest expansion of the regulator’s efforts to eliminate animal ...

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The Pixar Era kicked off 30 years ago with the first installment of the popular franchise. It’s given us countless hits, but something has also been lost. By Maya Phillips There are so many ways of ...

Respiratory syncytial virus (RSV) is a common respiratory virus which usually causes mild, cold-like symptoms during the respiratory virus season. However, especially among young infants under six ...

Primary nephrotic syndrome in adults is characterized by severe proteinuria and hypoalbuminemia. This was the first clinical trial to test rituximab in adult-onset frequently relapsing nephrotic ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...

There are currently 20 animations customized for different genres, including sports, pets, and travel videos. There are currently 20 animations customized for different genres, including sports, pets, ...

Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives each year worldwide with limited efficacy in currently available treatments ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...